Drug Profile
BMS 932481
Alternative Names: BMS-932481; Gamma secretase modulator - Bristol-Myers SquibbLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antidementias
- Mechanism of Action Amyloid precursor protein secretase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Alzheimer's disease in USA (PO) (Bristol-Myers Squibb pipeline, March 2023)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 13 Aug 2013 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in healthy volunteers (including elderly) presented at the 2013 Alzheimer's Association International Conference (AAIC-2013)